An investigational antisense oligonucleotide, zorevunersen targets the sodium voltage-gated channel alpha subunit 1(SCN1A) gene, which is the primary cause of most Dravet syndrome cases.

Zorevunersen is an investigational antisense oligonucleotide (ASO) that targets the SCN1A gene, the underlying cause of most cases of Dravet syndrome. Stoke recently announced plans to initiate a ...

DS is primarily caused by mutations in the SCN1A gene, which encodes the α subunit (Nav1.1) of the voltage-gated sodium channel (VGSC) in neuronal cell membranes. However, mutations in SCN1B can ...

Zorevunersen is an investigational antisense oligonucleotide (ASO) that targets the SCN1A gene, the underlying cause of most cases of Dravet syndrome. Stoke recently announced plans to initiate a ...

Zorevunersen, an investigational antisense oligonucleotide that targets the SCN1A gene, was designed to treat the underlying cause of Dravet syndrome. 1 “With Biogen’s deep experience in neurology and ...

Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet syndrome in all territories outside Canada, Mexico and the US. Dravet syndrome ...